<DOC>
	<DOCNO>NCT02019355</DOCNO>
	<brief_summary>The main purpose study determine effectiveness new combination therapy actinic keratosis . This study investigate new indication FDA-approved topical medication , calcipotriol , treatment actinic keratosis , include well work safe use combination standard care medication ( 5-fluorouracil ) skin condition .</brief_summary>
	<brief_title>Actinic Keratosis Study</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Petrolatum</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Age least 50 year Presence four fifteen clinically typical , visible , discrete actinic keratoses 25 cm2 four anatomical site : scalp , face , right upper extremity leave upper extremity Ability willingness patient participate study ( Informed consent obtain ) Treatment area within 5 cm incompletely heal wound suspect basalcell squamouscell carcinoma Treatment area contain hypertrophic hyperkeratotic lesion , cutaneous horn , lesion respond repeat cryotherapy Recent ( within month ) use medication could interfere evaluation treatment area ( e.g. , topical medication , artificial tanner , immunosuppressive medication , immunomodulating agent , cytotoxic drug , ultraviolet B phototherapy , therapies actinic keratoses , oral retinoids ) Premenopausal Women ( avoid risk pregnancy ) History hypercalcemia clinical evidence vitamin D toxicity</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>